# US 11,306,292 B2 · Stable virus-containing composition > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 11,306,292 B2 - Document ID: US11306292B2 - Status: Granted - Kind: B2 - Application number: 16/611,339 - Filed: 2018-05-15 - Published: 2020-05-28 - Granted: 2022-04-19 - Earliest claimed: 2017-05-15 - Assignees: Janssen Vaccines & Prevention B.V. - Applicants: Janssen Vaccines & Prevention B.V. - Inventors: Ahmad Shakeb Sediq; Wouter Frank Tonnis; Martinus Anne Hobbe Capelle - Web page: https://patentgrep.com/patent/US11306292B2 ## CPC - A61K 39/12: Viral antigens - C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00) - A61K 39/285: Vaccinia virus or variola virus - A61K 47/20: containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids - A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin - A61K 2039/525: {Virus} - C12N 2710/24121: Viruses as such, e.g. new isolates, mutants or their genomic sequences - C12N 2710/24122: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes - C12N 2710/24134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein - Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00) - Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE ## Abstract Described are compositions comprising enveloped viruses that are not MVA, a sulfate salt at a concentration of about 5 mM to about 300 mM and a buffer, and the composition has a pH of about 6.0 to about 8.5. It also discloses methods for stabilizing an enveloped virus composition by preparing said viral formulation. ## Claims ### Claim 1 A composition comprising a) an enveloped virus; b) a buffer selected from the group consisting of a Tris buffer, a phosphate buffer, a histidine, a citrate buffer, and a citrate/phosphate buffer, at a concentration of about 5 to about 40 mM; c) a sulfate salt selected from the group consisting of sodium sulfate, potassium sulfate, magnesium sulfate and an ammonium sulfate at a concentration of about 5 mM to about 300 mM; and d) glycerol at a concentration ranging between about 1% (w/w) to 6% (w/w), wherein said composition has a pH of about 6.0 to about 8.5, and the enveloped virus is not a MVA virus that expresses a Filovirus antigen. ### Claim 2 (depends on 1) The composition of claim 1, wherein the enveloped virus is not a MVA virus. ### Claim 3 (depends on 1) The composition of claim 1, wherein the enveloped virus is selected from the group consisting of influenza viruses, respiratory syncytial viruses (RSV), and herpes simplex viruses. ### Claim 4 (depends on 1) The composition of claim 1, wherein the enveloped virus is a recombinant enveloped virus. ### Claim 5 (depends on 1) The composition of claim 1, wherein the composition is a liquid composition or liquid frozen. ### Claim 6 (depends on 1) The composition of claim 1, wherein the buffer is a Tris buffer at a pH of about 6.5 to about 8.5, or a pH of about 7.5 to about 8.5, or a pH of about 8; or wherein the buffer is a phosphate buffer at a pH of about 6.5 to about 8.5, or a pH of about 6.8 to about 7.8, or a pH of about 7.0 to about 7.5. ### Claim 7 (depends on 1) The composition of claim 1, wherein the sulfate salt concentration is about 5 mM to about 150 mM. ### Claim 8 (depends on 1) The composition of claim 1, wherein the buffer is a Tris buffer at a concentration of about 10 mM, the sulfate salt is sodium sulfate at a concentration of about 100 mM, and wherein said composition has a pH of about 8; or wherein the buffer is a phosphate buffer at a concentration of about 10 mM, the sulfate salt is sodium sulfate at a concentration of about 100 mM, and wherein said composition has a pH of about 7.5. ### Claim 9 (depends on 1) The composition of claim 1, further comprising sodium chloride at a concentration of about 10 mM to about 100 mM. ### Claim 10 (depends on 1) The composition of claim 1, wherein the glycerol concentration is about 5% (w/w). ### Claim 11 (depends on 1) A pharmaceutical composition comprising the composition of claim 1. ### Claim 12 (depends on 1) A method of preparing the composition of claim 1, comprising combining a) the enveloped virus; b) the buffer selected from the group consisting of a Tris buffer, a phosphate buffer, a histidine, a citrate buffer, and a citrate/phosphate buffer, at a concentration of about 5 to about 40 mM; c) the sulfate salt selected from the group consisting of sodium sulfate, potassium sulfate, magnesium sulfate and an ammonium sulfate at a concentration of about 5 mM to about 300 mM; and d) glycerol at a concentration ranging between about 1% (w/w) to 6% (w/w), wherein said composition has a pH of about 6.0 to about 8.5. ### Claim 13 (depends on 1) A method of stabilizing an enveloped virus, comprising preparing the composition of claim 1 comprising the enveloped virus. ### Claim 14 (depends on 13) The method of claim 13, further comprising storing the composition at a temperature from 2 degrees centigrade to 8 degrees centigrade.